No products in the cart.
SAYPHA® VOLUME PLUS with Lidocaine
Active Substance(s) : Hyaluronic acid, lidocaine
Pack Size: 1-1ml prefilled syringe
Accessories: Package Insert
Saypha® Volume Plus Lidocaine is intented for severe facial wrinkles, loss of volume, and to improve facial contours. The product has a very high elasticity and ability to increase the skin volume. Saypha® Volume Plus Lidocaine improves skin vitality, firmness and glow. The result is a more youthful appearance. This dermal filler is the replacement for the previous Princess Volume Plus Lidocaine.Treatment for severe and deep facial wrinkles, loss of volume, and improvement of facial contours.
|1 - 5
|6 - 10
|11 - 20
Frequently Asked Questions
Saypha Volume Plus with Lidocaine is a dermal filler containing hyaluronic acid (HA). It is administered to restore facial volume as well as treat contour irregularities that emerge due to age. This product provides lift, hydration, and shape to the face. Saypha is manufactured by Croma-Pharma, a European company.
Made of non-animal HA: This filler contains non-animal sourced HA, which makes it more tolerable.
Contains an anesthetic: This product contains lidocaine, which minimizes discomfort during treatment.
One 1ml prefilled syringe
Two 27G½” needles
With age, the hyaluronic acid content in the skin declines, leading to the development of wrinkles, lines, and sunken areas. Saypha Volume Plus with Lidocaine is injected into the deep dermis to restore volume. It works to re-establish natural hyaluronic levels. This product helps for contouring, reshaping, and volumizing. Saypha offers delivery of instant results that are long lasting.
Hyaluronic acid (25mg/ml)
Saypha Volume Plus with Lidocaine provides effects of treatment that can last for about a year.
Minimal recovery time is needed after a Saypha Volume Plus with Lidocaine injection session.
This treatment is not suitable for people who are hypersensitive to hyaluronic acid or lidocaine hydrochloride.
Patients with active infection in the planned treatment sites should delay their injection until the infection has resolved.